Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGM
$3.90
-0.10 (-2.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-35.9M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$489M
P/E
N/A
•EV/EBITDA
N/A
•ROE
248.9%
↑Gross Margin
58.3%
↑Debt/Equity
-1.26
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
-5.0%
FCF CAGR
—
FCF margin
-119.0%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.5M · net income $-83.8M · FCF $-53.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $44.5M | $44.5M | $57.6M | $50.6M | $47.7M | $50.8M | $45.8M | $52.6M | $67.4M | $66.9M |
| Net Income | $-83.8M | $-83.8M | $-44.1M | $-7.9M | $-54.4M | $-70.5M | $-55.8M | $-66.2M | $-61.4M | $-8.9M |
| EBITDA | $-66.1M | $-66.1M | $-26.6M | $1.2M | $-39.6M | $-31.7M | $-39.5M | $-49.8M | $-45.7M | $3.6M |
| EPS | — | — | -0.51 | -0.13 | -1.12 | -1.85 | -1.66 | — | — | — |
| Gross Margin | 58.3% | 58.3% | 69.0% | 58.8% | 59.3% | — | — | — | — | — |
| Operating Margin | -159.5% | -159.5% | -53.5% | -29.9% | -88.2% | -68.2% | -93.6% | -100.1% | -72.6% | -0.2% |
| Net Margin | -188.1% | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | -121.7% | -125.9% | -91.0% | -13.4% |
| Balance Sheet | ||||||||||
| Debt/Equity | -1.26 | -1.26 | -0.63 | -0.31 | -0.48 | — | -1.06 | -11.43 | — | — |
| Current Ratio | 4.10 | 4.10 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-53.0M | $-53.0M | $-35.9M | $-7.4M | $-12.3M | $-33.9M | $-46.0M | $-60.9M | $-14.8M | $3.8M |
| Returns | ||||||||||
| ROE | 248.9% | 248.9% | 73.4% | 7.4% | 45.9% | 85.9% | 115.0% | 1082.1% | -608.9% | 33.8% |
| Valuation | ||||||||||
| EV/EBITDA | — | — | — | 129.26 | — | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | -22.6% | -22.6% | 13.8% | 6.1% | — | 10.9% | -12.8% | -22.0% | 0.8% | — |
| EPS Growth | — | — | -292.3% | 88.4% | — | -11.4% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+38.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.51 → n/d
Residual
+38.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.